30571-54-1

Basic information

• Product Name: Ribose tetracetate
• Synonyms: TETRAACETYLRIBOSERIBAVIRIN
• CAS NO: 30571-54-1
• Molecular Formula: C₁₃H₁₈O₉
• Molecular Weight: 318.28
• Mol File: 30571-54-1.mol
• Article Data: 4

Chemical Properties

• Melting Point: 110 °C
• Boiling Point: 410.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.245±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Ribose tetracetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ribose tetracetate(30571-54-1)
• EPA Substance Registry System: Ribose tetracetate(30571-54-1)

Safety Data

• Hazardous Substances Data: 30571-54-1(Hazardous Substances Data)

Upstream product

• 7226-49-5 2,3,4,5-tetra-O-acetyl-D-xylose diethyl dithioacetal 
• 58-86-6 D-xylose 
• 108-24-7 acetic anhydride 
• 59-23-4 D-Galactose 

Downstream Products

• 7208-41-5 penta-O-acetyl-6-deoxy-L-glucitol 
• 7208-41-5 penta-O-acetyl-1-deoxy-D-iditol 
• 50-69-1 D-ribose 
• 3051-94-3 3,4-dimethyl-N-ribitylaniline 
• 77976-96-6 9-((triacetyl)-β-D-ribofuranosyl)-N²-(p-tolyl)guanosine 
• 74458-63-2 phenyl 2,3,5-tri-O-acetyl-1-seleno-β-D-ribofuranoside 
• 339270-66-5 cis/trans-5-(2-benzyloxyethyl)-2-D-ribo-(1',2',3',4'-tetraacetoxybutyl)-1,3-dioxane 
• 77976-95-5 N²-p-tolyl-9-β-D-ribofuranosylguanine 
• 3615-56-3 D-Sorbose 
• 551-68-8 D-psicose 
• 74458-57-4 C₃₄H₃₈O₁₄Se₂ 
• 74458-55-2 1-α-phenyl selenyl-2,3,5-tri-O-acetylribose 
• 86334-50-1 1-deoxy-D-gulitol 
• 102455-13-0 2,3,4,5-Tetra-O-acetyl-1-D-(p-toluolsulfonyl)-ribitol 

Relevant articles and documents

Indiosides G-K: Steroidal glycosides with cytotoxic and anti-inflammatory activities from Solanum violaceum

Five new steroidal glycosides (1-5) and nine known compounds were isolated from Solanum violaceum. Indiosides G (1) and H (2) are spirostene saponins with an iso-type F ring, indioside I (3) is a spirostane saponin, and indiosides J (4) and K (5) are unusual furostanol saponins with a deformed F ring. These structures represent rare naturally occurring steroidal skeletons. The structures of the new compounds were elucidated using 1D and 2D spectroscopic techniques and acid hydrolysis. Compounds 2, 3, and 7-9 exhibited cytotoxic activity against six human cancer cell lines (HepG2, Hep3B, A549, Ca9-22, MDA-MB-231, and MCF-7) with IC50 values of 1.83-8.04 μg/mL. Steroidal saponins 3, 8, and 9 showed inhibitory effects on superoxide anion generation with IC50 values of 2.84 ± 0.18, 0.62 ± 0.03, and 1.62 ± 0.59 μg/mL, respectively. Saponins 8 and 9 also inhibited elastase release with IC50 values of 111.05 ± 7.37 and 4.04 ± 0.51 μg/mL, respectively. Structure-activity relationship correlations of these compounds with respect to cytotoxic and anti-inflammatory effects are discussed.

C-GLYCOSIDE ANALOGUES OF N-(4-HYDROXYPHENYL)RETINAMIDE-O-GLUCURONIDE

The present invention provides breast cancer chemopreventive arylamide analogues of retinoic acid, more particularly C-glycoside analogues of N-(4-hydroxyphenyl)retinamide-O-glucuronide and N-glycoside analogue of retinoyl beta-glucuronide that resist both beta-glucuronidase mediated enzymatic hydrolysis as well as acid catalyzed hydrolysis. Specifically, the drugs include 4-(retinamido)phenyl-C-glucuronide; 4-(retinamido)phenyl-C-glucoside; 4-(retinamido)benzyl-C-xyloside; 4-(retinamido)benzyl-C-glucoside; 4-(retinamido)benzyl-C-glucuronide; 4-(retinamido)phenyl-C-xyloside, 1-(B-D-lucopyranosyl) retinamide and 1-(D-glucopyranosyluronosly) retinamide. The invention also relates to a method for making such drugs.